Notice ID: b5f2231cfd834b45b56866bd68809210Presolicitation
Reagents and Kits for the Miltenyi CliniMACS Plus Instrument for Transfusion Medicine
Archived. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 10:00 AM UTC−04:00
- Posted
- March 3, 2023
- Notice type
- Presolicitation
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH - CC
- Place of performance
- Bethesda, MD, 20814
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- 23-002747
- Notice ID
- b5f2231cfd834b45b56866bd68809210
Description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. The National Institute of Health, Clinical Center (CC) intends to award a fixed price purchase order to Miltenyi Biotech, Inc, Auburn, CA 95602 on a sole source basis for a four month base period and three (3) one year option periods to procure reagents and testing kits necessary for patient testing in the Cell Processing Section (CPS) of the Department of Transfusion Medicine. The CPS is responsible for the manufacture of human cells and tissue-based products utilized in clinical protocols for transplantation, adoptive immunotherapy, and gene therapy. Miltenyi Biotech is the only known vendor that can supply the proprietary reagents and kits that are Federal Drug Administration (FDA) approved for clinical/human use. The stated reagents and kits are used for the preparation of highly purified but unique immunotherapy products for treatment of critically ill patients enrolled in FDA and Institutional Review Board (IRB) approved protocols. These specialized reagents and kits are the only known products compatible with the existing government owned Miltenyi CliniMACS Plus cell separation instrument. Any deviation from the protocol must be reported to FDA for non-compliance. The necessary estimated schedule of supplies is listed below to begin around May 1.: Year Estimated Usage Attached. 130-030-401 304-01 - CliniMACS CD4 MicroBeads - 1 vial 7,5 mL, For research use only, not for use in humans 130-030-801 308-01 - CliniMACS CD8 MicroBeads - 1 vial 7,5 mL. For research use only, not for use in humans 170-076-147 - MACS GMP Recombinant Human IL-2, 1 vial 500 ?g 130-019-011 - MACS GMP T Cell TransAct, RUO, 1 vial 4 mL 130-070-525 705-25 - CliniMACS PBS/EDTA Buffer for research use contents: 3 x 1L plastic bags, sterile, non-pyrogenic - 130-021-201 212-01 - CliniMACS PBS/EDTA Buffer for Research Use consists of: 2 x 3L plastic bags, sterile, non-pyrogenic, 170-076-306 - TexMACS GMP Medium 1 bag 2000mL 170-076-111 - MACS GMP Recombinant Human IL-7 1 vial 25 ?g, 170-076-114 - MACS GMP Recombinant Human IL-15 1 vial 25 ?g, This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 . Simplified Acquisition Procedures, Subpart 13.5, Simplified Procedures for Certain Commercial Products and Commercial Services for other than full and open competition. One source is deemed uniquely capable to provide the products. 13.501 Special documentation requirements will be followed for sole source (including brand name) acquisitions. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Malinda Dehner, Contract Officer, dehnerm@cc.nih.gov by the due date and time marked in this notice.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
23-002747- Pre-Solicitation
Formal solicitation typically follows within 30–60 days. (estimate)
- Pre-SolicitationCurrentMar 3, 2023
Reagents and Kits for the Miltenyi CliniMACS Plus Instrument for Transfusion Medicine
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. | 68% | Pre-Solicitation | 11/11/2026 |
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith the format in FAR Subpart 12.6, as supplemented with additional information includedin this notice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00017. This solicitation is issued as a Notice ofIntent (NOI) for a non-competitive combined synopsis/solicitation to award a contract orpurchase order without providing for full and open competition (including brand-name, ifapplicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a purchase order on a non-competitive basis to Purdue University, Purdue Institute for Drug Discovery (DRUG), 575 Stadium Mall Drive, West Lafayette, IN 47907, for the synthesis, scale-up, and characterization of lead Spleen Tyrosine Kinase (SYK) inhibitors in support of the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Rationale for non-competitive award: The proposed acquisition is a continuation of project-specific medicinal chemistry work under the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Dr. Philip S. Low's laboratory at Purdue University is the identified extramural medicinal chemistry collaborator for this project and has performed the prior design and synthesis work associated with the SYK inhibitor candidates being advanced under the study. The Year 1 requirement is specifically for the synthesis, scale-up, and characterization of lead SYK inhibitors S1115 and S1213 for subsequent biological evaluation by NIH investigators. Purdue possesses the project-specific knowledge and experience associated with these compounds. Use of another source would require duplication of prior research before the source could continue the current effort, resulting in delay and technical risk. Based on these circumstances, Purdue University is the only source reasonably available to perform this specific Year 1 requirement. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325411, Medicinal and Botanical Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business. | 63% | Combined Synopsis | 11/04/2026 |
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Takeda Pharmaceutical Company Limited. The National Institutes of Health (NIH) Clinical Center (CC) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. This includes the purchase of Gammagard S/D 10gm and Gammagard S/D 5gm kits. The NIH CC Pharmacy is requesting the purchase of 10 bottles each of Gammagard S/D 10gm and Gammagard S/D 5gm kits and as needed to provide anticipated current patient care need. Justification: TAKEDA Group is the only responsible source for Gammagard S/D. There are multiple patients in the NIH currently on therapy with Gammagard S/D and additional patients may be transferred to the NIH for evaluation and treatment. Gammagard S/D is on the Clinical Center’s formulary, requiring a supply to be available in the Pharmacy Department at all times to support ongoing patient care. The NIH needs to keep using the same items to keep treatment consistent. | 61% | Pre-Solicitation | 11/16/2026 |
Quotes must be submitted by email to Mohammed Hussain at Mohammed.Hussain2@va.gov by September 21, 2026, at 15:00 PM PT. To be considered for award, quotes must include: 1. Price Factor complete the price schedule in Section B.2 PRICE/COST SCHEDULE | 59% | Sole Source / J&A | Open |
THIS REQUEST FOR INFORMATION (RFI) / SOURCES SOUGHT NOTICE IS ISSUED SOLELY FOR INFORMATION AND PLANNING PURPOSES. THIS IS NOT A SOLICITATION. SUBMISSION OF INFORMATION ABOUT PRICING, DELIVERY, THE MARKET, AND CAPABILITIES IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS RFI FOR PLANNING PURPOSES IN ACCORDANCE WITH (IAW) FAR 15.201(e). DISCLAIMER This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. IAW FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. SOURCES SOUGHT/RFI DESCRIPTION This is NOT a solicitation announcement. This is a Sources Sought Notice / RFI only. The purpose of this Sources Sought Notice / RFI is to gain information about potential qualified sources and their size classification relative to NAICS 325412 (size standard of 1,300 Employees). Responses to this Sources Sought Notice / RFI will be used by the Government to make appropriate acquisition decisions. After review of the responses to this Sources Sought Notice / RFI, further RFIs and/or a solicitation or other announcements may be published. STATEMENT OF WORK Manufacturing and delivery of sterile/aseptic, USP 825 compliant, low enriched uranium (LEU) radiopharmaceuticals for diagnosis and treatment of patients receiving services at VA San Diego Healthcare System Nuclear Medicine Service. Delivery services must meet all DOT requirements for shipment and delivery of radioactive drugs. Stat delivery services (within 1 hour) must be available 24hrs/day 365 days/year. Companies providing services must provide dose labels compatible with the Nuclear Medicine information System (NMIS) computerized radiopharmacy database. Companies must provide storage, preparation, labeling and delivery of research radiopharmaceuticals as requested. Base January 1, 2027, through December 31, 2027 OY 1 January 1, 2028, through December 31, 2028 OY 2 January 1, 2029, through December 31, 2029 OY 3 January 1, 2030, through December 31, 2030 OY 4 January 1, 2031, through December 31, 2031 PARTICIPATING VA HEALTHCARE SYSTEMS: VA San Diego Healthcare System 3350 La Jolla Village Drive Nuclear Medicine Service San Diego, CA 92161 2. ROUTINE ORDERS Routine orders require delivery the next business day, unless specified elsewhere in this contract. 3. EMERGENCY ORDERS Stat delivery services (within 1 hour) must be available 24hrs/day 365 days/year. 4. PRICE/COST SCHEDULE Description Estimated Min Quantity UOM Unit Price I-123 USP NaI 200 uCi capsules 35 EA I-123 USP NaI 2 mCi 3 EA I-123 USP NaI 4 mCi 3 EA I-123 Iobenguane Sulfate (I-123 Adreview MIBG) 1 I-131 USP NaI DX cap per mCi (4mci) 10 EA I-131 USP NaI TX cap per mCi (150mci) 10 EA In-111 Pentetreotide (Octertide/Octeoscan) UD 1 EA In-111 Pentetate (DTPA) SDV/Vial 1 EA In-111 Autologuous WBCs tagging, pick-up and delivery 9 EA In-111 WBC Blood Kit (Heparin) 9 EA 99mTc Mertiatide (MAG3) UD 38 EA 99mTc Sulfur colloid UD ( Filtered ) 10 EA 99mTc Sulfur colloid UD 90 EA 99mTc Macro Aggregated Albumin (MAA) UD 220 EA 99m Tc High Concentrated (Technegas) 25mCi 150 EA 99m Tc Pentetate (DTPA)UD 1 EA 99mTc dimercaptosuccinic acid (DMSA) UD 1 EA 99mTc Medronate (MDP) UD 300 EA 99mTc Sestamibi (Cardiolite®) UD DO NOT SUBSTITUTE 3400 EA 99mTc PYP or (HDP) 50 EA 99mTc NaTco4 UD per mCi 30 EA 99mTc Mebrofenin (Choletec)UD 25 EA Tl-201 Thallious Chloride UD 1 EA Ga-67 Gallium Citrate UD 1 EA GA-68 DOTATATE (NET-SPOT) 15 EA Macro Aggregated Albumin Vial 0 Pentetate Vial 0 EA Medronate Vial 0 EA Ultra-tag kit 4 Hep-lock for RBC Tag 4 Standard scheduled delivery 3-4 per/day  Stat Delivery Service (within 1 hour) available 24 hours/day 8 After hours call out 4 Heparin vial 4 Heparin/Hetastarch Syringe 9 TOTAL 5. DELIVERY LOCATION, NORMAL WORK HOURS AND INSTRUCTIONS: Delivery Location Nuclear Medicine Service, Main Hospital, 4 West, 4th Floor Normal Work Hours 7:00am to 4:00pm, Monday through Friday 6. PACKAGING AND MARKING a) The contractor shall package, mark and transfer all radioactive material in accordance with all applicable local, state, and federal regulations. b) Items must be properly packaged to prevent damage during shipping, handling, and storage. c) All outer packages must contain the complete purchase number, obligation number and contract number in addition to the shipping address. The purchase number and obligation number will be provided by the individual at the time of ordering. The contract number will be provided upon notice of contract award. d) Packaging List: A packing list/slip shall be enclosed with each shipment indicating the purchase/obligation and delivery order number, contract number, items/quality ordered, and items/quality shipped. 7. RECALLED AND DEFECTIVE PRODUCTS The Contractor will immediately notify the Contracting Officer of any recalls of product or other important product safety issues. As appropriate, the Contractor will replace and/or reimburse recalled / defective products at no cost to the Government. The Contractor may be liable for costs of processing recalls, i.e. administrative and clinical services to replace recalled / defective products. 8. SAFETY GUIDELINES AND REQUIREMENTS The Contractor shall perform all functions of the contract in compliance with Occupational Safety and Health Administration (OSHA), FDA, NRC, Joint Commission safety guidelines and Department of Transportation (DOT) requirements. The Contractor shall self-report any violations to the point of contact (POC) within twenty-four (24) hours. Delivery personnel shall be trained in Radiation Safety Techniques, Nuclear Regulatory Commission, Joint Commission safety guidelines and Department of Transportation requirements. 9. NATIONAL HOLIDAYS OBSERVED BY THE GOVERNMENT New Year s Day January 1 Martin Luther King s Birthday 3rd Monday in January Presidents Day 3rd Monday in February Memorial Day Last Monday in May Juneteenth June 19 Independence Day July 4 Labor Day 1st Monday in September Columbus Day 2nd Monday in October Veterans Day November 11 Thanksgiving Day 4th Thursday in November Christmas Day December 25th The President of the United States of America may declare additional days as a federal holiday, and if so, this holiday will automatically be added to the list above. When a holiday falls on a Sunday, the following Monday shall be observed as a Federal holiday. When a holiday falls on a Saturday, the preceding Friday shall be observed as a Federal Holiday. 10. CONTRACTOR DELIVERY PERSONNEL All contractor personnel are required to wear clothing bearing the name of the Contractor and wear a badge that has the Contractor name. Contractor personnel must have a picture I.D. and must be able to speak English. 11. PARKING AND SPEED LIMIT Park only in areas designated by the Contracting Officer Representative (COR) or otherwise directed by Police and Security Service personnel. The Contractor shall display on each of its vehicles the company name in a size that is clearly visible. Upon receipt of award, the Contractor shall submit a list of employees and vehicles to the COR of each facility. The Contractor shall conform to the speed limit set at each Government facility. Should Contractor personnel receive a citation for parking, speeding or other infraction from VA Security, the offenses will be handled in Federal Court as they are Federal offenses. 12. INVOICE AND PAYMENT No advanced payments will be authorized. The contractor shall submit invoices monthly. The invoice must have at a minimum, the contract number, assigned purchase order, assigned obligation number, date order was placed, date order was shipped, and any additional necessary detailed information to identify service rendered. Payment on invoice may be delayed in invoice(s) are not completed properly. NOTE: Potential quoters must be aware that the items being acquired are procured as Brand Name or Equal. For those items that are or equal , a description of the salient characteristics is outlined below. It is quoter s responsibility to demonstrate its quote meeting the salient physical and functional characteristics included in this solicitation. If the quote does NOT demonstrate, the offer will be considered non-responsive. The interested parties bear full responsibility to ensure their submission demonstrates to the government that they can satisfy the requirement by providing the brand name or equal to the supplies being requested. VAAR 852.212-71 Gray Market and Counterfeit Items clause applies on this acquisition. No remanufacturers or gray market items will be acceptable. Vendor shall be an Original Equipment Manufacturer (OEM), authorized dealer, authorized distributor or authorized reseller verified by an authorization letter or other documents from the OEM signed. The letter must either state specific product(s) quoted or that the quoter is an authorized distributor for all the manufacturer s products. This letter must be on the manufacturer s letterhead and contains the signature of an authorized official for the manufacturer. If the interested contractor fails to provide a signed letter from the OEM (unless the contractor is the OEM), the contractor s response will be deemed non-responsive and will not be considered for award. The list of DRAFT characteristics is intended to be descriptive, not restrictive, of the supplies/services that are required. If your company is interested and capable of providing the required supplies/services, please provide the information indicated below. Response to this notice should include company name, address, point of contact, size of business pursuant to the following questions: (1) Submit your capabilities statement illustrating how your organization can/cannot meet the list of SOW requirements. For instances where your company cannot meet the SOW requirement(s), please explain. For instances where your company can meet the SOW requirement(s), please show how your company meets/exceeds each requirement. (2) Please review the list of SOW requirements and provide any additional feedback or suggestions. If none, please reply as N/A. (3) Please indicate the size status and representations of your business, such as but not limited to: Service-Disabled Veteran-Owned Small Business (SDVOSB), Veteran-Owned Small Business (VOSB), HUBZone, Woman Owned Small Business (WOSB), Large Business, etc. (4) Is your company considered small under the NAICS code identified in this RFI? (5) Are you the manufacturer, authorized distributor, and/or can your company provide a solution to the required supplies/services described in the list of SOW? (6) If you are a large business, do you have any designated/authorized distributors? If so, please provide their company name, telephone, point of contact and size status (if available). (7) If you re a small business and you are an authorized distributor/reseller for the items identified above, do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified. (8) Limitations on Subcontracting: How does your business ensure compliance with the limitations on subcontracting as outlined in 13 CFR § 125.6? (9) Are the items you are identifying/providing considered Commercial of the Shelf (COTS) items as defined in FAR Part 2.101 under commercial items? (10) Non-Manufacturer Rule: If applicable, can you confirm your business complies with the Non-Manufacturer rule? Specifically, does your company: Provide a product from a small business manufacturer or processor? Not exceed 500 employees? Primarily engage in the retail or wholesale trade and normally sell the type of item being supplied? Take ownership or possession of the item(s) with its personnel, equipment or facilities in a manner consistent with industry practice? (11) Please indicate whether your product conforms to the requirements of the Buy American Act? (12) Does your company have a Federal Supply Schedule (FSS) GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract? If so, please provide the contract number(s). (13) If you are an FSS GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract holder, are all the items/solutions you are providing information about available on your schedule/contract? Please state if all or some items are available on the contract. (14) General pricing of your products/solution is encouraged. Pricing will be used for the purpose of market research only. It will not be used to evaluate for any type of award. (15) Please provide your SAM.gov Unique Entity ID/Cage Code number. Responses to this notice shall be submitted via email to Adrienne.Brown4@va.gov. Telephone responses will not be accepted. Responses must be received no later than Friday, November 6, 2026, by 10AM Mountain Time. All responses to this Sources Sought/RFI will be used for planning purposes only. Responses to this Sources Sought Notice / RFI are not considered a request to be added to a prospective bidders list or to receive a copy of the solicitation. If further RFIs and/or a solicitation or other announcement is issued as a result of the information provided from this RFI, all interested parties must respond to the specific posting separately IAW the specifications of that announcement. | 57% | Market Research | 11/06/2026 |
Additional Details
Solicitation Number
23-002747
Archive Date
Not specified
Office Address
BETHESDA, MD, 20892